TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34462864
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 4 weeks + topical corticosteroids (TCS)
Study: 34462864
Drug: Dupilumab 100
Normalized name: DUPILUMAB 100MG/0.67ML INJ,SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 100 or 200 mg every 2 weeks + TCS
Study: 33228511
Drug: Omacor 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor 2 g/day
Study: 39075484
Drug: Aspirin continuation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin continuation
Study: 34718493
Drug: Aspirin discontinuation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin discontinuation
Study: 35676012
Drug: Durable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durable polymer drug-eluting stents (DP-DES)
Study: 34696674
Drug: Theophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200 mg/day)
Study: 33524545
Drug: Neoadjuvant ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant ADT for 6 months starting 4 months before prostate radiation therapy
Study: 33524545
Drug: Adjuvant ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant ADT for 6 months starting simultaneously with prostate radiation therapy
Study: 32166681
Drug: 80 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kVp, 270 mgI/mL
Study: 32166681
Drug: 100 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp, 270 mgI/mL
Study: 32166681
Drug: 100 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp, 320 mgI/mL
Study: 32166681
Drug: 100 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp, 400 mgI/mL
Study: 32794481
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy (cervical isometrics and targeted muscle stretchings)
Study: 35266184
Drug: Capacitive resistive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capacitive resistive monopolar radiofrequency (CRMRF) treatment at 448 kHz
Study: 35266184
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment with the same physiotherapeutic techniques
Study: 34218053
Drug: Dexamethasone 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1.8 mg daily
Study: 32975383
Drug: Urinary catheter
Normalized name: urinary catheter maintenance solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary catheter removal timing in rectal surgery
Study: 36286741
Drug: Bifiform 2
Normalized name: CATHETER,URETHRAL 9FR,FILIFORM TIP DILATION BALLOON #G17843
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifiform 2 capsules 2 times a day for 2 weeks, along with mebeverin 200 mg 2 times a day or trimebutin 200 mg 3 times a day for 4 weeks, rifaximin 400 mg 3 times a day or nifuroxazide 400 mg 2 times a day for 1 week, and a drug that normalizes feces consistency (dioctahedral smectite or macrogol 4000)
Study: 36286741
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received similar therapy without Bifiform
Study: 36271257
Drug: Intraventricular KCl
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraventricular KCl injection
Study: 36271257
Drug: Interventricular septal
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventricular septal KCl administration
Study: 35852527
Drug: Omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv mecarbil (n = 185), given orally twice daily at a dose of 25 mg, 37.5 mg, or 50 mg for 20 weeks.
Study: 35852527
Drug: Placebo (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (n = 91), given orally twice daily for 20 weeks.
Study: 35938324
Drug: Micro‐needle knife
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro‐needle knife therapy
Study: 35938324
Drug: Betahistine mesilate
Normalized name: Betahistine mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine mesilate tablets (6 mg, three times a day for 14 days)
Study: 39334205
Drug: Proton-pump inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitors
Study: 35561151
Drug: Oral ultramicrosize
Normalized name: GRISEOFULVIN,ULTRAMICROSIZE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ultramicrosize griseofulvin (Group A)
Study: 33740751
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection with triamcinolone hexacetonide (40 mg)
Study: 36356613
Drug: Setmelanotide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setmelanotide (up to 3.0 mg subcutaneous once per day for 14 weeks)
Study: 33960840
Drug: Original balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original balloon dilator (created with two middle fingers of a #8 powder‐free surgical glove tied to a nondisposable 11 mm trocar and filled with 600 mL of saline)
Study: 34635391
Drug: CYD‐TDV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD‐TDV vaccine
Study: 33225989
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (2000 mg daily in the form of two 'Fish Oil, Ultra Omega-3' capsules)
Study: 33225989
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 identical placebo capsules daily)
Study: 35996760
Drug: Dementia VR-based
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dementia VR-based training with peer support (3-month e-book modules, VR activities, 1-hour monthly peer support meetings)
Study: 35996760
Drug: Non-VR control
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-VR control group (3-month e-book modules, 1-hour monthly regular staff meetings)
Study: 35498786
Drug: Monthly motivational
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly motivational interviews on smoking reduction, 8-week nicotine replacement therapy, referral to smoking cessation service
Study: 33069608
Drug: Feedback-guided exercises
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback-guided exercises using the ReHand tablet application
Study: 36223848
Drug: tezepelumab plus
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tezepelumab plus subcutaneous cat SCIT
Study: 32839200
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil + probiotics combination
Study: 36173066
Drug: Lurasidone 20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20-80 mg/d
Study: 35643872
Drug: Enriched seafood
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enriched seafood sticks (50 g/day containing 1010 CFUs of heat-inactivated B. animalis subsp. lactis CECT8145, 370 mg/day omega 3, and 1.7 g/day inulin)
Study: 35643872
Drug: Enriched seafood
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enriched seafood sticks (50 g/day)
Study: 35643872
Drug: Placebo seafood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo seafood sticks (50 g/day)
Study: 32933355
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to treatment (exact intervention details not specified)
Study: 33755884
Drug: Upadacitinib 6
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib 6 mg BID
Study: 33755884
Drug: Upadacitinib 6
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib 6 mg BID or higher
Study: 33755884
Drug: Upadacitinib 6
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib 6 mg BID and 24 mg BID
Study: 33755884
Drug: Upadacitinib 12
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib 12 mg BID
Study: 32171316
Drug: PAT‐A© intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAT‐A© intervention (individualised psychological treatment for anxiety)
Study: 36037303
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in combination with chemoradiation (chemoRT)
Study: 32759096
Drug: Transannular pericardial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transannular pericardial patch (TAP)
Study: 32473596
Drug: Antithrombotic agents
Normalized name: ANTITHROMBOTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic agents (especially heparin-based regimens)
Study: 34195468
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g soluble corn fiber (SCF)
Study: 34195468
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg calcium
Study: 34195468
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g SCF plus 600 mg calcium
Study: 33262113
Drug: Connected pre-habilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Connected pre-habilitation program during neoadjuvant chemotherapy
Study: 35495881
Drug: Classical theory
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical theory of Traditional Chinese Medicine (TCM)
Study: 34126996
Drug: Tart Cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart Cherry (TC) 500 mg
Study: 35910406
Drug: Ultrasound-guided intercostal
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intercostal nerve block with 0.25% ropivacaine and 5 mg dexamethasone
Study: 35910406
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) with fentanyl
Study: 34593232
Drug: Tributyrin supplementation
Normalized name: Tributyrin
DrugBank: Tributyrin (DB12709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tributyrin supplementation at 1 g/L
Study: 34593232
Drug: Tributyrin supplementation
Normalized name: Tributyrin
DrugBank: Tributyrin (DB12709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tributyrin supplementation at 2 g/L
Study: 34593232
Drug: Tributyrin supplementation
Normalized name: Tributyrin
DrugBank: Tributyrin (DB12709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tributyrin supplementation at 1 g/L and 2 g/L
Study: 36167528
Drug: MERM device-observed
Approvals — FDA: no, EMA: no, PMDA: no
Description: MERM device-observed self-administered therapy
Study: 36167528
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard in-person directly observed therapy)
Study: 36240801
Drug: 210 mg
Normalized name: aspirin 210 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 210 mg etrolizumab induction
Study: 36240801
Drug: 105 mg
Normalized name: menthol 105 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg etrolizumab maintenance
Study: 36240801
Drug: 105 mg
Normalized name: menthol 105 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg etrolizumab induction
Study: 34717532
Drug: Dexmedetomidine (1 μg kg‐ 1)
Normalized name: dexmedetomidine 0.1 MG/ML
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (1 μg kg‐ 1)
Study: 34717532
Drug: Lidocaine (1.5 mg kg‐ 1)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg kg‐ 1) with additional propofol (0.5 mg kg‐ 1)
Study: 32174775
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol/remifentanil
Study: 34281311
Drug: Concentrated growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated growth factors (CGF) associated with implants
Study: 34281311
Drug: Standard implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard implant treatment (Control)
Study: 35235632
Drug: Taper thread
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper thread on straight-body implants with microthreads (group A)
Study: 35235632
Drug: Taper thread
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper thread on straight-body implants without microthreads (group B)
Study: 35235632
Drug: Implants inserted
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants inserted with IT > 50 Ncm
Study: 32245513
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of xenon and dexmedetomidine
Study: 34965510
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of Dexamethasone (LoDex arm) with standardized physical activity for 4 weeks
Study: 34965510
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of Dexamethasone (HiDex arm) with standardized physical activity for 4 weeks
Study: 33656569
Drug: oral cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral cladribine
Study: 34795034
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg via HandiHaler daily for 6 months
Study: 33755976
Drug: Hemoperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoperfusion therapy
Study: 35177299
Drug: Moderna vaccine
Normalized name: Moderna COVID-19 Vaccine
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderna vaccine
Study: 33636147
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine, BBV152
Study: 36413230
Drug: 8 mg/d
Normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/d of extended-release morphine
Study: 36413230
Drug: 16 mg/d
Normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/d of extended-release morphine
Study: 36413230
Drug: 24 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg/d of extended-release morphine
Study: 36413230
Drug: 32 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg/d of extended-release morphine
Study: 32144641
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy (DBT) adapted for bipolar disorder
Study: 34726114
Drug: GLN (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLN (0.3 g kg FFM-1)
Study: 34137904
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dextroamphetamine
Study: 32102920
Drug: pCONUS HPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: pCONUS HPC device with single antiplatelet therapy (SAPT) using acetylsalicylic acid (ASA)
Study: 35303938
Drug: Continuous renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous renal replacement therapy (CRRT) and CytoSorb for 72 hours
Study: 33140125
Drug: Selenised yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenised yeast supplementation at 100, 200, and 300 μg Se/day for 6 months
Study: 33140125
Drug: Selenised yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenised yeast supplementation at doses over 100 μg Se/day for 5 years
Study: 35437837
Drug: Eliapixant (10-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant (10-800 mg)
Study: 35713888
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (BAT) + guideline-directed medical therapy (GDMT)
Study: 38773653
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (normal saline)
Study: 35123401
Drug: Basmisanil 120
Normalized name: Basmisanil
DrugBank: Basmisanil (DB11877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basmisanil 120 mg BID
Study: 35123401
Drug: Basmisanil 240
Normalized name: Basmisanil
DrugBank: Basmisanil (DB11877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basmisanil 240 mg BID
Study: 35123401
Drug: Basmisanil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basmisanil (both doses)
Study: 33381933
Drug: DW‐7202 (capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DW‐7202 (capsule type)
Study: 32069068
Drug: Driving pressure-limited
Approvals — FDA: no, EMA: no, PMDA: no
Description: Driving pressure-limited strategy (ventilated with volume-controlled or pressure-support modes, tidal volume titrated to 4-8 ml/kg of predicted body weight, aiming for a driving pressure of 10 cm H2O or the lowest possible)
Study: 32069068
Drug: Conventional lung-protective
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional lung-protective ventilation strategy (ARDSNet protocol, tidal volume of 6 ml/kg PBW, adjustable to 4 ml/kg PBW if plateau pressure >30 cm H2O)
Study: 32890016
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen (HFNO) at 10 l/min before sedation and 50 l/min during the procedure
Study: 32890016
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen face mask at 10 l/min during the procedure
Study: 35134988
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (brief counseling)
Study: 35134988
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (sustained counseling plus smoking cessation medication)
Study: 32358379
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined therapy
Study: 32715917
Drug: Bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab treatment with urine protein monitoring every other treatment
Study: 32715917
Drug: Bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab treatment with urine protein monitoring every third treatment
Study: 33248880
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with rush immunotherapy for 2 weeks, followed by a gradual increase of cow's milk volume to 100 mL for 1 year.
Study: 33847224
Drug: Misoprostol utilization
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol utilization not continued beyond 6 doses or 24 h
Study: 35580191
Drug: Rivaroxaban (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10mg once daily for 3 weeks starting 7±2 days after surgery)
Study: 33185002
Drug: glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride 1 to 4 mg
Study: 37019385
Drug: ivarmacitinib 2
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivarmacitinib 2 mg once daily
Study: 37019385
Drug: ivarmacitinib 4
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivarmacitinib 4 mg once daily
Study: 37019385
Drug: ivarmacitinib 8
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivarmacitinib 8 mg once daily
Study: 32917556
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI (18/9.6 μg)
Study: 32852428
Drug: 595-nm Pulsed
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595-nm Pulsed Dye Laser treatment (fluence 7.5 J/cm2, 3-ms pulse duration, no dynamic cooling, 10-mm spot size, 10% overlap between pulses, 2 stacked pulses)
Study: 32852428
Drug: Sham/control treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham/control treatment
Study: 32559817
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment (immune or targeted therapy)
Study: 32559817
Drug: LDH >500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDH >500 U/L
Study: 35674759
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules containing multi-strain at least 1.6×10^9 CFU/g bacteria
Study: 32665035
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 300 mg
Study: 32665035
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) (low or moderate dose)
Study: 32674675
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg (R10)
Study: 32674675
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg (R15)
Study: 32674675
Drug: DAPT (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (aspirin 75 mg and clopidogrel 75 mg)
Study: 32674675
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg (R10) and Rivaroxaban 15 mg (R15)